Research comparing HIV medications set to change international recommendations
The WHO-funded study shows that dolutegravir is the optimal choice for first-line treatment of HIV
Read MoreJuly 5, 2017
The WHO-funded study shows that dolutegravir is the optimal choice for first-line treatment of HIV
Read More
Today is Injury Prevention Day in Canada. This bonus edition of the Evidence Speaks will feature a more detailed look at policy-informing research on traumatic brain injury and helmet legislation by CHÉOS Scientists.
Read More
This bonus edition of the Evidence Speaks will feature a more detailed look at relevant, policy-informing research on HIV by CHÉOS Scientists.
Read More
The third installment in our new series, "The Evidence Speaks," highlighting the latest in CHÉOS research.
Read More
The second post in our new series, "The Evidence Speaks," highlighting the latest in CHÉOS research.
Read More